PharmaFocus Today – Page 20 – media

The National Medical Insurance Administration responded to the next direction of the centralized procurement of consumables

Recently, the National Medical Insurance Administration issued the “Reply of the National Medical Insurance Administration to Suggestion No. 2090 of the Second Session of the Fourteenth National People’s Congress” (hereinafter referred to as the “Reply”). In the “Reply”, the National Medical Insurance Administration explained the next steps for the centralized procurement of consumables and the implementation of innovative medical devices. In particular, the next steps for local centralized procurement were explained. The “Reply” pointed out that centralized procurement is still in the stage of reform and overcoming difficulties. The National Medical Insurance Administration will further supervise and improve the rules of local centralized procurement, improve the scientificity and standardization of local centralized procurement, and improve the quality and efficiency of procurement. First, expand the scope of the alliance and strengthen national coordination. Encourage local governments to carry out alliance procurement, and upgrade to national alliance procurement if conditions are met. ...
- Source: drugdu
- 60
- October 9, 2024
14 major consumables enter price reduction period

At the end of September, the National Joint Procurement Platform for High-value Medical Consumables issued the “Notice on the Centralized Maintenance of Cochlear Implants and Peripheral Interventional Medical Consumables”. At present, many provinces have begun to start the historical procurement data reporting work for this national procurement. The reporting subjects are public medical institutions that use cochlear implants and peripheral interventional medical consumables in 2022 and 2023. The deadline is around October 16 and 17. At 15:00 on October 8, the National Joint Procurement Office for High-value Medical Consumables will introduce the system operation through video conferencing, and provide training videos and other materials for use by various medical institutions. Peripheral intervention is one of the few varieties that have not yet been purchased on a large scale. This national procurement is bound to have a major impact on this field. In 2021, Henan’s centralized procurement of neuro-interventional and peripheral ...
- Source: drugdu
- 68
- October 9, 2024
With a dividend rate of 100% and a profit growth rate of nearly 40%, Dong-E-E-Jiao has resumed high growth

In recent days, various stimulus policies designed from the top have been launched, giving the long-dull stock market a long-lost vitality. On September 30, the Shanghai Composite Index closed up 8.06%, standing above 3,300 points, with a cumulative increase of more than 17% in September; the Shenzhen Component Index closed up 10.67%, with a cumulative increase of more than 26% in September; the ChiNext Index closed up 15.36%, with a cumulative increase of more than 37% in September; all set a record for the largest single-day increase in history. On that day, the turnover of the two markets was 2.593 trillion yuan, setting a record high since 2006. The activity of funds has risen unprecedentedly, and once exceeded the carrying capacity of the exchange server during the session. Players in the market are gearing up to “do a big job”. However, the pharmaceutical industry has been subject to many restrictions ...
- Source: drugdu
- 65
- October 9, 2024
Electrophysiology, giants dance wildly

The existing electrophysiology market is very considerable, and the incremental market has unlimited potential. Research institution BTIG predicts that half of atrial fibrillation ablations may be replaced by PFA in the next three years. In the new business of PFA, electrophysiology giants dare not be tired at all. Recently, Boston Scientific announced that it has obtained approval from Japanese regulators for the FARAPULSE™ pulsed field ablation system. Nick Spadea-Anello, president of Boston Scientific Electrophysiology, said that the FARAPULSE PFA system is the most clinically studied PFA system. To date, it has been used to treat more than 125,000 patients worldwide and continues to strengthen its strong safety, effectiveness and efficiency characteristics. “The rapid adoption of the FARAPULSE PFA system, which is now approved in more than 65 countries, demonstrates a paradigm shift in the treatment of paroxysmal atrial fibrillation – an approach that has clinical benefits for both physicians and ...
- Source: drugdu
- 72
- October 8, 2024
Licensed Pharmacists Decreased

According to the National Medical Products Administration’s Licensed Pharmacist Qualification Certification Center, from the end of April to the end of July this year, the cumulative number of licensed pharmacists in the country with valid registration has decreased month-on-month. In April, May, June, and July, the number of registered licensed pharmacists nationwide decreased by 1,940, 685, 4,384, and 88 respectively. In recent years, the number of retail pharmacies in my country has continued to grow. As of the end of December 2023, the number of pharmacies nationwide exceeded 666,000, including 14,792 wholesale enterprises, 6,725 retail chain headquarters, 385,594 retail chain stores, and 281,366 single pharmacies. These data have increased compared to 2022. The total number of retail pharmacies continues to increase, and the society has a strong demand for licensed pharmacists, but the number of registered licensed pharmacists has decreased in several months. The General Department of the State Drug ...
- Source: drugdu
- 92
- October 8, 2024
What does it mean to have a dual system in healthcare?

On September 8, the Ministry of Commerce, the National Health Commission, and the State Food and Drug Administration jointly issued the Notice on Carrying out Pilot Work on Expanding Opening-up in the Medical Field (hereinafter referred to as the “Notice”). It is proposed to allow the establishment of wholly foreign-owned hospitals (except for traditional Chinese medicine, excluding mergers and acquisitions of public hospitals) in Beijing, Tianjin, Shanghai, Nanjing, Suzhou, Fuzhou, Guangzhou, Shenzhen and Hainan. This is undoubtedly a bold innovation to the existing healthcare system. Previously, foreign investment was limited to joint venture hospitals, and there were many restrictions such as shareholding ratio. With the relaxation of policy restrictions and the introduction of foreign-funded medical institutions, as more high-end medical institutions enter the Chinese market, while diverting some high-end patients, it may also improve the development and progress of the overall medical level in China. There are two main points ...
- Source: drugdu
- 77
- October 6, 2024
What is the impact of the House of Representatives’ passage of the draft biosafety law amid the controversy on WuXi

On September 9, the House of Representatives of the United States Congress returned from a summer break and immediately scheduled a series of legislative votes, including the draft Biosafety Act (H.R. 8333). The draft biosecurity law passed the House of Representatives with 306 votes in favor and 81 votes against, but the 70% support rate made it the most divisive draft bill in the same batch, and even narrowly fell below the “bottom line” of more than two-thirds of the votes to pass the bill. The draft Biosafety Act places five companies, including WuXi AppTec and WuXi Biologics, on the list of “biotechnology companies of concern” on the grounds of “national security”, and intends to restrict the use of funds, loans or subsidies from the United States government to cooperate with these companies. Unlike previous committees that voted in small groups, this time there were several members of the House ...
- Source: drugdu
- 74
- October 6, 2024
The old mechanism of “using drugs to support doctors” has been broken

Recently, the State Council Information Office held a series of press conferences on “Promoting High-quality Development”. The leadership of the National Health Commission answered many questions in the field of domestic medicine and health at the meeting. When introducing the basic situation, Lei Haichao, director of the National Health Commission, said that the National Health Commission adheres to the public welfare and works with relevant departments to deepen the medical reform. Over the past decade, especially since the 18th National Congress of the Communist Party of China, the old operating mechanism of using drugs to support doctors and consumables to support doctors has been historically broken, and a new operating mechanism dominated by medical services has been initially established. The income of public medical institutions has changed from the original three channels to two channels of government financial subsidies and medical service charges. “The old mechanism of relying on ...
- Source: drugdu
- 96
- October 5, 2024
sell right, sell well, and sell for a long time

First, the essence of business is market competition, and the market is the battlefield. Business people should have a sales mindset, and salespeople need to have a business perspective. There is a view that sales and business are different positions in pharmaceutical companies, with different responsibilities and assessment standards, and it is difficult to integrate the two positions, so you can focus on your own duties. However, the performance appraisal of most pharmaceutical companies is still stuck in the “butt determines the head” standard, and there is rarely a global vision of “the head decides the butt”. It is beneficial for sales and business to empathize, but it cannot completely resolve all conflicts and disputes. At the time of the transformation of the pharmaceutical industry, cross-disciplinary talents who are both proficient in sales and business are increasingly becoming valuable resources for enterprises to compete for. The business position in the ...
- Source: drugdu
- 75
- October 5, 2024
Digital therapeutics are a big failure

The digital therapeutics industry has evolved and evolved beyond all expectations. In June 2021, Pear Therapeutics, the “first stock of digital therapeutics”, was listed; In April 2023, he filed for bankruptcy and bankruptcy; A year later, Better Therapeutics, another star digital therapeutics company, also fell; Four months ago, Akili chose to sell himself and delist and go private. So far, the three musketeers of overseas digital therapeutics have all fallen. If you count from the listing of Pear, a three-year cycle, the waves will sweep away the heroes. On the surface, the main reason for the collapse of these companies is financial problems, but the deeper reason is the commercialization challenges faced by digital therapeutics. The challenge is that digital therapeutics need to have drug-like efficacy in order to gain market acceptance, but the embarrassment is that prescription digital therapeutics are not drugs per se, but more about using technical ...
- Source: drugdu
- 57
- October 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.